Shareholder Updates

Viewing stories tagged shareholder

16 April 2012

In this issue:

› Starpharma commences pivotal phase 3 VivaGel^® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

20 December 2011

In this issue:

› Starpharma raises $35m to advance pipeline

› Starpharma signs with Ansell for condom coating

› Putting a stop to stubborn BV: The VivaGel^© solution

› Clinical trials for VivaGel^©gather pace

› M&G invests $20 million

› Dendrimers through the eyes of Professor Donald Tomalia

26 July 2011

In this issue:

› VivaGel® demonstrates efficacy in the treatment of bacterial vaginosis; Independent study finds link between bacterial vaginosis and HIV

› Japanese VivaGel® condom deal secures second largest condom market in the world

› Starpharma’s Priostar dendrimers improve bestselling herbicide

› Drug delivery program delivers early-stage results in improving blockbuster chemo drug.

29 March 2011

In this issue:

› Enrolment completed for Phase2 study of VivaGel® for treatment of BV

› Strengthening shareholderbase – new domestic and European investors

› Broad appeal of SPL’sdendrimer technology platform – agrochemicals and drug delivery

› Starpharma’s performance vs the market

Download: Shareholder Update: March 2011 ( pdf file, 530kb)

12 ... Next